When Gabrielle Richens opened the episode of the Aesthetics Today Podcast with a sponsor thank‑you to Digital Aesthetics, the set‑up sounded familiar. Another industry conversation about devices, procedures, and the ever‑moving frontier of “what’s next”. But the guest, Dr Ruthie Olumba, quickly moved the discussion somewhere more intimate, and, for many clinic owners, more commercially consequential. The idea that aesthetics can be an entry point into medicine, not a detour from it.
Dr Ruthie describes her work as sitting “at the intersection of women’s health and aesthetics”, a phrase that, in lesser hands, might land as branding. In this conversation, it became a clinical argument, that women are often well supported during pregnancy, but spend most of their lives not pregnant, navigating body changes that affect confidence, function, and health. That “in‑between” is where she believes aesthetic practice has an ethical opportunity, and a business advantage, if it learns to see the whole patient.
Dr Ruthie’s pivot into aesthetics began in the operating theatre, not on Instagram. Early in her career, she trained as a reproductive surgeon focused on uterine fibroids, benign uterine growths that can still cause outsized disruption through heavy bleeding, pelvic pressure, pain, and fertility problems. In mainstream care, hysterectomy is often positioned as the definitive solution, but uterus‑sparing options such as myomectomy can be appropriate for women who want symptom relief while preserving fertility or the uterus itself.
Then, she said, the post‑operative conversations changed. Patients returned not with questions about surgical scars or blood counts, but with something more existential. “You did such a good job…I got pregnant…now I’ve had the baby…and what is this…this ‘mommy body’?” It was a moment that many aesthetic clinicians will recognise. The realisation that outcomes women want are rarely confined to one anatomical problem. They are trying to reconcile a life event with what they see in the mirror, and with how they feel inside it.
A device sales visit, an attempt to sell her the radiofrequency microneedling platform Morpheus8, became a hinge point. She resisted the “extra” of aesthetics until she spoke to other gynaecologists who had already integrated cosmetic surgery into women’s care. What stayed with her was not the promise of a new revenue stream, but one colleague’s regret. Abandoning women’s health entirely to do only cosmetics.
Confidence wasn’t her “before and after”
One of the most affecting parts of the episode was Dr Ruthie’s rejection of a common assumption. That people pursue surgery because they “don’t love themselves”. In her experience, she said, many women seek surgery because they do, because they have already dieted, trained, and tried, and are choosing to invest in themselves rather than apologise for wanting change.
To illustrate, she told a story about a woman who arrived hunched, styled beautifully but trying to disappear under the weight, physically and emotionally, of extremely large breasts. Other surgeons had declined to operate because of the recognised risks in complex breast reductions, including compromised blood supply to the nipple‑areola complex in very large lifts. The operation went ahead, the results mattered. But what followed is what Dr Ruthie framed as the real outcome. the patient’s posture changed, her wardrobe shifted from all black to colour, and, most strikingly, she climbed professionally, earning promotions and eventually becoming a vice president. As the patient put it, “you helped me see life in colour again.”
This is anecdote, not data. Yet the underlying theme aligns with what research repeatedly finds. Breast reduction and abdominoplasty can improve quality of life, body satisfaction, and self‑esteem in many patients, often alongside functional benefits such as reduced discomfort and improved physical ease. The point the episode made, quietly but firmly, is that the “after” patients buy is not simply a silhouette. It is permission to re‑enter their lives with less hiding.
GLP‑1 era is changing body contouring
The discussion then pivoted to the most obvious macro‑force now reshaping aesthetic demand, GLP‑1 receptor agonists. Dr Ruthie spoke about the flood of patients arriving post‑weight loss with loose skin and altered body proportions. That trend is visible well beyond one clinic. Plastic surgery organisations and market analysts have documented increasing interest in post‑GLP‑1 skin‑tightening and body contouring consultations, and recent research has found an association between GLP‑1 use and subsequent aesthetic body contouring surgery.
She offered two practical reframes for patients and practitioners. First, body contouring is not weight loss. Liposuction “sucks fat”, it targets localised subcutaneous fat resistant to lifestyle change, and it is not a substitute for diet, exercise, or obesity treatment. Second, rapid weight loss comes with physiological trade‑offs that show up in surgical outcomes. Hence nutrition, muscle, and bone health.
The scientific concern here is real even if the clinic language varies. Rapid weight reduction on GLP‑1 therapies can include loss of lean mass. One academic health overview describes substantial lean mass loss during rapid weight change, and peer‑reviewed work continues to examine GLP‑1 impacts on skeletal muscle. Bone health is also an active research area. A randomised clinical trial found that combining exercise with a GLP‑1RA strategy preserved bone health better than GLP‑1RA treatment alone, suggesting the protective effect of structured training during pharmacological weight loss.
Dr Ruthie’s advice is that “the day you get GLP‑1s is the day you dedicate the rest of your life to strength training”, was deliberately vivid. The evidence supports the direction, even if each patient needs individual medical guidance. Resistance training and adequate protein are standard tools for preserving muscle and supporting recovery, and higher protein intake is commonly recommended in peri‑operative nutrition for tissue repair.
Insta is selling step 2000 while patients are on step 1
If the GLP‑1 conversation was about biology, the social media conversation was about psychology, and, crucially, expectation management. Dr Ruthie described a recurring clinic dynamic with patients bring in a body they want, but the image represents a whole, often undisclosed surgical journey, multiple rounds of liposuction, implants, fat transfer, editing, lighting, pose, condensed into a single “result”.
There is growing evidence that social media shapes cosmetic procedure intent and body image, and that digitally altered ideals can create demands that no scalpel should promise to deliver. In the UK, advertising regulators have repeatedly acted against misleading “before and after” imagery and the exaggeration of efficacy, an external pressure that increasingly forces clinics to treat marketing as part of patient safety.
Dr Ruthie also made an ethical stand that many clinicians will recognise as harder than it sounds. Refusing to “out” celebrities for alleged work they have not disclosed. She called celebrities “human beings with a loud microphone” and framed her role as education, not surveillance, while still using openly discussed examples, including Simone Biles, to normalise bodily autonomy without feeding “outing culture”.
Her deeper concern, though, was what she called the “policing” of women’s faces, online commentary insisting someone “looked better before”. In her view, it teaches women that they can invest heavily in themselves and still be denied validation, which is why she interrogates motivation in consultation. That fits with a wider clinical reality, where a meaningful minority of cosmetic patients may screen positive for body dysmorphic disorder (BDD), and many experts now argue for routine screening to protect patients and practitioners.
The most radical proposal in the episode was also the simplest. “We need to practise medicine, not just fix anatomy.”
Dr Ruthie argues that aesthetics clinics, where women already show up, can become a point of access for health conversations that otherwise never happen. That matters because the patient base is overwhelmingly female. Industry reporting suggests women comprise the large majority of medical aesthetics patients, and surgical statistics consistently show women receive most cosmetic procedures.
Her example was PCOS, which is common, underdiagnosed, metabolically significant, and frequently tangled with weight, skin changes, and fertility planning. Global prevalence estimates vary by criteria but consistently place PCOS in the high single to low double digits, with major bodies noting that many cases remain undiagnosed. If a woman presents for liposuction because she “can’t lose belly fat”, Dr Ruthie wants clinicians to know enough to ask if is this hormonal, metabolic, perimenopausal?
The menopause link is not speculative. Oestrogen decline contributes to measurable changes in skin collagen, elasticity, and hydration, changes that aesthetic medicine often treats without naming the cause.
Her vision for clinic owners is both clinical and commercial. She calls for them to integrate small, relevant health questions, know who to refer to, build continuity. Done well, she argues, you become less like a transactional service provider and more like the trusted professional women return to, “like a hairstylist”, but medically competent.
Regenerative medicine and why “old and trusty” still wins
When the conversation turned to regenerative aesthetics, Dr Ruthie pushed back against hype without dismissing innovation. Platelet‑rich plasma (PRP), she said, is “old and trusty”, and she uses it for wound healing support, scar management, hair rejuvenation, and sexual wellness. The evidence is mixed by indication, but far from imaginary, meta‑analyses suggest PRP can improve hair density in androgenetic alopecia, although protocols and study quality vary. In female sexual dysfunction and urogenital applications, systematic reviews and trials indicate possible benefits, while emphasising heterogeneity and the need for stronger standardised evidence.
On exosomes and stem‑cell‑adjacent products, she was more cautious, calling much of the current marketplace “marketing more than evidence‑based”. Regulators have issued stark warnings that there are no FDA‑approved exosome products and that unapproved cell‑derived interventions can carry serious risks, a reality that clinics must understand before selling “regeneration” as certainty.
That cautionary stance is, in itself, a thread that runs through the whole episode. The future of aesthetics is bright, Dr Ruthie believes, but only if it grows into clinical maturity, where the consultation is deeper, the claims are cleaner, and the patient is treated as a whole woman across a whole lifespan, not a single procedure on a single day.
